In an exclusive interview with Financial Express, Sriram Natarajan, Director and CEO of Molbio Diagnostics, outlined the company’s commitment to expanding the Truenat platform to cover a broader spectrum of diseases. Having already transformed TB and COVID-19 testing with its portable, point-of-care molecular diagnostics, Molbio now plans to introduce tests for antimicrobial resistance, clostridium difficile, and more TB variants. With Truenat devices present in over 40 countries and growing global demand, Molbio is positioning itself to become one of the world’s largest point-of-care solution providers. The company is also exploring strategic acquisitions to strengthen its portfolio and drive its goal of universal access to quality diagnostics.
